Compare AVLN & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | ATEC |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2026 | 2006 |
| Metric | AVLN | ATEC |
|---|---|---|
| Price | $26.27 | $11.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $61.80 | $15.79 |
| AVG Volume (30 Days) | 266.3K | ★ 2.0M |
| Earning Date | 11-25-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.04 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $101,739,000.00 |
| Revenue This Year | N/A | $15.43 |
| Revenue Next Year | N/A | $15.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.24 | $6.82 |
| 52 Week High | $40.17 | $23.29 |
| Indicator | AVLN | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 59.02 |
| Support Level | $24.90 | $10.61 |
| Resistance Level | $30.45 | $11.54 |
| Average True Range (ATR) | 1.73 | 0.49 |
| MACD | 0.45 | 0.04 |
| Stochastic Oscillator | 72.23 | 74.59 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.